The US Association for Accessible Medicines has released a new white paper pointing to shortcomings in Medicare Part D that it says are delaying access to first generics. The AAM found that first generics face “significant delays in Part D formulary coverage and are routinely placed on expensive brand drug tiers with higher patient cost-sharing.”
The white paper also found that commercial health insurance plans are slow to achieve full coverage for new generics....




